Top 30 Pharmaceutical Companies in Bangladesh 2026

.

Introduction

The pharmaceutical industry of Bangladesh continues to demonstrate strong growth, supported by increasing healthcare demand, expansion of local manufacturing, rising chronic disease prevalence, improved access to medicines, and increasing investment in pharmaceutical manufacturing and healthcare infrastructure.

According to the IQVIA 2Q 2026 data, the Bangladesh pharmaceutical market recorded a MAT value of BDT 40,885 crore, representing 10.61% growth. During QTR 2Q 2026, the market generated approximately BDT 10,735 crore, with a strong 14.39% growth.

The market remains highly competitive, with leading domestic pharmaceutical companies maintaining significant market share. Square Pharmaceuticals continues to hold the number-one position, followed by Incepta Pharmaceuticals and Beximco Pharmaceuticals.

This article presents the Top 30 Pharmaceutical Companies in Bangladesh in 2026, based on their MAT and QTR performance for 2Q 2026.

Bangladesh Pharmaceutical Market Size 2026

The pharmaceutical market of Bangladesh has maintained a strong growth trajectory in 2026.

According to the supplied IQVIA 2Q 2026 data:

MAT 2Q 2026 Market Value: BDT 40,885 crore

MAT Growth: 10.61%

QTR 2Q 2026 Market Value: BDT 10,735 crore

QTR Growth: 14.39%

The figures indicate that the industry is experiencing stronger short-term quarterly momentum compared with the annual MAT growth rate.

Quarterly Performance of Bangladesh Pharmaceutical Industry

The QTR 2Q 2026 market reached approximately BDT 10,735 crore, registering 14.39% growth.

This strong quarterly performance reflects continued demand for pharmaceutical products across major therapeutic categories.

Among the leading companies, several manufacturers recorded double-digit QTR growth. Particularly notable were:

-OSL Pharma: +204.69%

-Everest Pharma: +113.68%

-Synovia Pharma PLC: +45.48%

-Healthcare Pharma: +16.53%

-Beximco: +15.58%

-Square: +15.14%

-Incepta: +15.98%

-Nevian Lifescience: +12.39%

The quarterly data therefore shows that a number of smaller and emerging pharmaceutical companies are expanding rapidly, although their absolute market values remain much smaller than those of the leading companies.

What is the Top 20 Pharmaceutical Company in Bangladesh?

Major Growth Drivers of Bangladesh Pharmaceutical Market

Several factors continue to support the growth of Bangladesh’s pharmaceutical industry.

1. Increasing Healthcare Demand

Bangladesh’s growing population and increasing healthcare awareness are driving demand for pharmaceutical products.

2. Expansion of Chronic Disease Treatment

The increasing prevalence of diabetes, cardiovascular diseases, hypertension, kidney disease and other chronic conditions is supporting sustained pharmaceutical demand.

3. Growth of Local Manufacturing

Bangladesh has developed a strong domestic pharmaceutical manufacturing base, with local companies producing a wide range of generic medicines.

4. Increasing Healthcare Access

Improved access to hospitals, clinics, diagnostic facilities and pharmacies is contributing to greater medicine consumption.

5. Pharmaceutical Innovation and Product Expansion

Leading pharmaceutical companies are continuously expanding their product portfolios, entering new therapeutic segments and introducing specialized medicines.

6. Strong Domestic Competition

Competition among local pharmaceutical manufacturers has encouraged companies to improve manufacturing capabilities, product quality, distribution networks and marketing strategies.

Top Companies Dominating the Bangladesh Pharmaceutical Market

The Bangladesh pharmaceutical market remains concentrated among a relatively small number of leading companies.

Top 3 Pharmaceutical Companies in Bangladesh Dominate 39.30% of Market Share

Based on the supplied IQVIA MAT 2Q-2026 data, the Top 3 pharmaceutical companies—Square Pharmaceuticals, Incepta Pharmaceuticals, and Beximco Pharmaceuticals—collectively account for 39.30% of Bangladesh’s pharmaceutical market, representing approximately Tk. 16,069 crore out of the total selected market of Tk. 40,885 crore. Square Pharmaceuticals alone holds 16.96% (approximately Tk. 6,936 crore), followed by Incepta Pharmaceuticals with 12.57% (approximately Tk. 5,139 crore)andBeximco Pharmaceuticals with 9.77% (approximately Tk. 3,994 crore). This concentration demonstrates the strong market position of the three leading pharmaceutical companies in Bangladesh.

Top 5 Pharmaceutical Companies in Bangladesh Dominate 52.46% of Market Share

The Top 5 pharmaceutical companies collectively dominate 52.46% of Bangladesh’s pharmaceutical market, equivalent to approximately Tk. 21,449 crore based on the supplied MAT 2Q-2026 figures. In addition to Square, Incepta, and Beximco, Healthcare Pharmaceuticals and Renata further strengthen the market concentration. The Top 5 companies therefore control more than half of the selected pharmaceutical market, highlighting the significant influence of Bangladesh’s leading pharmaceutical manufacturers.

Top 10 Pharmaceutical Companies in Bangladesh Dominate 74.64% of Market Share

The Top 10 pharmaceutical companies account for 74.64% of Bangladesh’s pharmaceutical market, representing approximately Tk. 30,514 crore of the Tk. 40,885 crore selected market. The group includes Square, Incepta, Beximco, Healthcare Pharmaceuticals, Renata, Eskayef (SK+F), Aristopharma, Opsonin Pharma, Popular Pharma, and Radiant. With nearly three-quarters of the market concentrated among just 10 companies, the data demonstrates the highly competitive yet concentrated structure of Bangladesh’s pharmaceutical industry.

Top 15 Pharmaceutical Companies in Bangladesh Dominate 88.84% of Market Share

The Top 15 pharmaceutical companies collectively dominate 88.84% of Bangladesh’s pharmaceutical market, corresponding to approximately Tk. 36,318 crore based on the supplied MAT 2Q-2026 data. The Top 15 include the country’s major domestic pharmaceutical manufacturers as well as several important multinational and specialized players. Controlling almost 89% of the market, these companies represent the overwhelming majority of pharmaceutical sales within the selected market.

Top 30 Pharmaceutical Companies in Bangladesh Dominate 99.14% of Market Share

The Top 30 pharmaceutical companies collectively account for 99.14% of Bangladesh’s pharmaceutical market, representing approximately Tk. 40,533 crore based on the market-share figures supplied for MAT 2Q-2026. The Top 30 therefore represent virtually the entire selected market of Tk. 40,885 crore. This indicates an exceptionally high level of market concentration among the leading pharmaceutical companies.

The remaining 0.86 percentage points correspond to approximately Tk. 352 crore based on the supplied total market value. Because the company-level market shares are displayed to two decimal places, this difference should be treated as an approximate residual rather than an exact measurement of all companies outside the Top 30.

List of Top 30 Pharmaceutical Companies in Bangladesh 2026

 (Based on IQVIA MAT 2Q-2026 Data)

The following list presents the Top 30 pharmaceutical companies in Bangladesh based on IQVIA MAT 2Q-2026 data. The ranking reflects pharmaceutical market performance and sales contribution during the relevant 12-month period.

What is MAT in Pharmaceutical Market Analysis?

MAT (Moving Annual Total) 2Q-2026 represents the rolling 12-month period ending June 2026 (July 2025–June 2026). MAT data provides a broader and more reliable view of company performance than a single-quarter analysis.

The ranking offers an overview of the leading pharmaceutical companies and their relative positions in Bangladesh’s pharmaceutical market.

Top 30 Pharmaceutical Companies in Bangladesh by MAT 2Q 2026

Data as : MAT: 2Q- 2026, 12 Months (July 2025 – June 2026)
MAT -2Q, 2026 Rank	Company Name	MAT Value (Cr. Tk.)	Market Share (%)	Growth (+/-)
1	Square Pharmaceuticals Ltd.	6,936	16.96	7.80
2	Incepta Pharmaceuticals Ltd.	5,139	12.57	8.89
3	Beximco Pharmaceuticals Ltd.	3,994	9.77	12.93
4	Healthcare Pharma	3,046	7.45	6.55
5	Renata Pharma	2,334	5.71	9.79
6	Eskayef (SK+F)	1,998	4.89	9.27
7	Aristopharma	1,918	4.69	18.88
8	Opsonin Pharma	1,899	4.65	9.47
9	Popular Pharma	1,637	4.00	7.40
10	Radiant	1,616	3.95	18.78
11	ACME	1,585	3.88	11.21
12	A.C.I.	1,530	3.74	9.61
13	Drug International	1,220	2.98	18.67
14	Unimed & Unihealth	910	2.23	5.39
15	Beacon Pharma	559	1.37	19.44
16	Ziska	471	1.15	32.35
17	Novo Nordisk	425	1.04	14.58
18	Nipro JMI Pharma	422	1.03	8.61
19	Ibn Sina	360	0.88	23.45
20	Nuvista Pharma	333	0.81	20.93
21	Sun Pharma	330	0.81	41.38
22	Navana Pharma	328	0.80	15.62
23	Synovia Pharma PLC	328	0.80	21.72
24	Nevian Lifescience	307	0.75	-0.68
25	Roche Bangladesh	281	0.69	4.61
26	Orion Pharma Ltd.	185	0.45	-9.14
27	Eli Lilly	162	0.40	7.48
28	Servier	162	0.40	11.50
29	Everest Pharma	67	0.16	44.73
30	OSL Pharma	52	0.13	84.34
Total	Selected Total	40,885	100.00	10.61

Top 30 Pharmaceutical Companies in Bangladesh – QTR 2Q 2026

The Top 30 pharmaceutical companies in Bangladesh are ranked based on their quarterly market performance during April–June 2026, using IQVIA QTR 2Q-2026 data. This ranking reflects quarterly sales, market contribution, and competitive position. IQVIA-based reporting indicates that the selected Bangladesh pharmaceutical market grew by approximately 14.39% in Q2 2026.

What is QTR in Pharmaceutical Market Analysis?

QTR 2Q-2026 represents the quarterly pharmaceutical market performance for April–June 2026. Unlike MAT, which covers a rolling 12-month period, QTR focuses only on the latest three months.

It provides a snapshot of quarterly sales, market share, growth, and competitive performance of pharmaceutical companies in Bangladesh.

Data as : QTR: 2Q- 2026, 3 Months (April 2026 – June 2026)
QTR 2Q 2026 Rank	Company Name	QTR 2Q Value (Cr. Tk.)	Market Share (%)	Growth (+/-)
1	Square Pharmaceuticals Ltd.	1,844	17.17	15.14
2	Incepta Pharmaceuticals Ltd.	1,387	12.92	15.98
3	Beximco Pharmaceuticals Ltd.	1,087	10.13	15.58
4	Healthcare Pharma	853	7.94	16.53
5	Renata Pharma	635	5.92	13.55
6	Eskayef Pharma	582	5.43	12.11
7	Aristopharma	484	4.51	10.53
8	Opsonin Pharma	482	4.49	15.59
9	Radiant	446	4.15	15.18
10	Popular Pharma	419	3.90	9.54
11	A.C.I.	416	3.88	12.05
12	ACME	361	3.36	11.49
13	Drug International	314	2.92	14.13
14	Unimed & Unihealth	244	2.27	8.56
15	Beacon Pharma	120	1.12	16.25
16	Nipro JMI Pharma	96	0.89	15.33
17	Novo Nordisk	85	0.79	8.19
18	Ziska	91	0.85	12.40
19	Ibn Sina	73	0.68	13.25
20	Nuvista Pharma	78	0.73	12.45
21	Sun Pharma	68	0.63	15.79
22	Navana Pharmaceuticals Ltd	73	0.68	11.25
23	Synovia Pharma PLC	92	0.86	45.48
24	Nevian Lifescience	80	0.74	12.39
25	Roche	80	0.75	7.53
26	Orion Pharma Ltd.	41	0.38	-6.90
27	Eli Lilly	35	0.33	8.45
28	Servier	40	0.37	10.59
29	Everest Pharma	20	0.19	113.68
30	OSL Pharma	18	0.17	204.69
Total	Selected Total	10,735	100.00	14.39

Remarkable Growth among Pharmaceutical Companies in Bangladesh 2026

One of the most interesting findings from the IQVIA MAT 2Q 2026 data is the strong growth achieved by several companies outside the traditional top tier. OSL Pharma recorded the highest MAT growth among the 30 companies listed, with an impressive 84.34% growth. Its QTR growth was even more remarkable at 204.69%, making it the fastest-growing company in the supplied QTR dataset. Everest Pharma also demonstrated exceptional performance, recording 44.73% MAT growth and 113.68% QTR growth, indicating strong recent expansion. Sun Pharma recorded 41.38% MAT growth, placing it among the fastest-growing companies in the MAT ranking, while Ziska achieved 32.35% MAT growth, demonstrating significant annual expansion.

Ibn Sina recorded 23.45% MAT growth, reflecting solid year-on-year performance. Synovia Pharma PLC achieved 21.72% MAT growth along with an impressive 45.48% QTR growth, highlighting strong momentum in recent quarters. Nuvista Pharma recorded 20.93% MAT growth, showing strong annual performance, while Beacon Pharma achieved 19.44% MAT growth. Aristopharma recorded 18.88% MAT growth, placing it among the stronger-performing pharmaceutical companies in the ranking. Meanwhile, Radiant achieved 18.78% MAT growth and 15.18% QTR growth, indicating consistent growth across both annual and quarterly measures. Overall, the data highlights a number of companies demonstrating significantly higher growth rates than the broader market, with OSL Pharma and Everest Pharma standing out particularly strongly in both MAT and QTR performance.

Top Growing Pharmaceutical Companies in Bangladesh 2026 (MAT 2Q)

Based on the supplied dataset, some of the most notable MAT growth rates are:

Among the companies listed, OSL Pharma recorded the highest MAT growth at 84.34%, followed by Everest Pharma at 44.73% and Sun Pharma at 41.38%. Ziska achieved 32.35% MAT growth, while Ibn Sina recorded 23.45%. Synovia Pharma PLC posted 21.72% growth, followed by Nuvista Pharma at 20.93%, Beacon Pharma at 19.44%, Aristopharma at 18.88%, and Radiant at 18.78%. Overall, the data shows particularly strong annual growth among OSL Pharma, Everest Pharma, Sun Pharma, and Ziska, with OSL Pharma standing out as the clear leader in MAT growth among the companies listed.

These growth figures demonstrate that the Bangladesh pharmaceutical market is not growing only through the largest companies; several mid-sized and emerging players are also expanding rapidly.

Top Growing Pharmaceutical Companies in Bangladesh 2026 (QTR 2Q)

The QTR data reveals even stronger short-term growth among some emerging companies.

The pharmaceutical companies with the highest QTR growth include OSL Pharma (204.69%), followed by Everest Pharma (113.68%) and Synovia Pharma PLC (45.48%). Other companies showing notable quarterly growth are Beacon Pharma (16.25%), Healthcare Pharma (16.53%), Incepta (15.98%), Opsonin Pharma (15.59%), Sun Pharma (15.79%), Beximco (15.58%), and Square (15.14%). Overall, OSL Pharma and Everest Pharma stand out with exceptionally high QTR growth compared with the other companies listed.

Square Pharmaceuticals Remains the Market Leader

Square Pharmaceuticals retained the number-one position in the Bangladesh pharmaceutical market according to the MAT 2Q 2026 data.

The company recorded:

      -MAT Value: BDT 6,936 crore

-MAT Market Share: 16.96%

-MAT Growth: 7.80%

-QTR Value: BDT 1,844 crore

-QTR Market Share: 17.17%

-QTR Growth: 15.14%

With nearly 17% market share, Square continues to maintain a substantial lead over other pharmaceutical companies.

Incepta Pharmaceuticals Holds the Second Position

Incepta Pharmaceuticals ranked second with:

-MAT Value: BDT 5,139 crore

-Market Share: 12.57%

-MAT Growth: 8.89%

-QTR Value: BDT 1,387 crore

-QTR Market Share: 12.92%

-QTR Growth: 15.98%

The company continues to be one of the strongest competitors in the Bangladesh pharmaceutical market.

Beximco Pharmaceuticals Remains in the Top Three

Beximco Pharmaceuticals ranked third with:

-MAT Value: BDT 3,994 crore

-Market Share: 9.77%

-MAT Growth: 12.93%

-QTR Value: BDT 1,087 crore

-QTR Market Share: 10.13%

-QTR Growth: 15.58%

Beximco’s double-digit MAT and QTR growth indicates strong market momentum during the period.

Popular Pharma Performance

Popular Pharma ranked 9th in MAT and 10th in QTR.

MAT 2Q 2026

-Rank: 9

-Value: BDT 1,637 crore

-Market Share: 4.00%

-Growth: 7.40%

QTR 2Q 2026

-Rank: 10

-Value: BDT 419 crore

-Market Share: 3.90%

-Growth: 9.54%

Popular therefore remains firmly positioned among Bangladesh’s leading pharmaceutical manufacturers.

Executive Summary

The Bangladesh pharmaceutical industry demonstrated strong performance in 2Q 2026.

According to the supplied IQVIA MAT/QTR 2Q 2026 dataset, the selected pharmaceutical market reached:

MAT 2Q 2026:
BDT 40,885 crore, with 10.61% growth

QTR 2Q 2026:
BDT 10,735 crore, with 14.39% growth

Square Pharmaceuticals maintained the leading position with 16.96% MAT market share, followed by Incepta Pharmaceuticals at 12.57% and Beximco at 9.77%.

The top three companies collectively accounted for approximately 39.30% of the market, while the top ten companies represented approximately 74.86%.

At the same time, several emerging companies demonstrated exceptionally high growth. OSL Pharma recorded the highest MAT growth at 84.34% and the highest QTR growth at 204.69%, while Everest Pharma also showed very strong growth.

Overall, the 2Q 2026 data indicates that Bangladesh’s pharmaceutical market continues to expand, while competition among established, mid-sized and emerging pharmaceutical companies remains intense.

Frequently Asked Questions (FAQs)

Data Source

Source: IQVIA – MAT 2Q 2026 / QTR 2Q 2026 data supplied for this article.

Market: Bangladesh Pharmaceutical Industry

Total MAT Market: BDT 40,885 crore
MAT Growth: 10.61%
Total QTR Market: BDT 10,735 crore
QTR Growth: 14.39%

Note: The rankings and figures in this article are based specifically on the IQVIA 2Q 2026 dataset provided for analysis. Company names, rankings, market values, market shares and growth percentages have been reproduced from the supplied data.